EVQLV uses machine learning to reduce the 90% failure rate of antibody discovery for biotechs and pharmaceutical companies. Since our product launch in May, we have signed 32 deals with 18 companies, including 4 multi-national pharmaceutical companies. As a result, EVQLV is a cash flow positive and profitable business.
Additional Info
Sponsor Type
StartUp